Diabetics with atrial fibrillation often develop other heart problems that could lead to death. But aggressive treatment can reduce the risk, an international study has found.
The findings were published in Europe's leading cardiology journal, the European Heart Journal on 12 March 2009.
The study of 11,140 patients with type 2 diabetes found that patients who had atrial fibrillation (AF) at the start of the trial had a 61 per cent increased risk of dying from any cause, a 77 per cent increased risk of dying from cardiovascular causes such as a heart attack or stroke, and a 68 per cent increased risk of developing heart failure or other cerebrovascular problems such as stroke, when compared with diabetic patients who did not have AF.
However, the study also found that if clinicians gave more aggressive treatments to the diabetic AF patients - in this study they treated them with a combination blood pressure lowering drugs, (perindopril and indapamide) - the risk of dying or developing any of these complications was reduced. It was also reduced in diabetic patients without AF who were given the same treatment.
Professor Anushka Patel, Director of the Cardiovascular Division at The George Institute for International Health (University of Sydney, Australia) and an Associate Professor in the Faculty of Medicine at the university, who led the study, said: "Active treatment produced similar relative benefits to patients with and without AF. However, because of their higher risk at the start of the study, the absolute benefit associated with active treatment was greater in patients with AF than without. We estimate that five years of active treatment would prevent one death among every 42 patients with AF and one death among every 120 patients without AF."
The findings have important implications for the management of diabetics and for policy in this area. Diabetes is a major global health problem, with an estimated worldwide prevalence of 2.8 per cent in 2000, projected to increase to 4.4 per cent in 2030. Atrial fibrillation is common in diabetic patients.
Prof Patel said: "The prevalence of AF varies greatly according to the population's age and other health problems.
"The number of diabetic patients is projected to increase to 380 million at 2025. We might expect that about 40 million of these will also have AF. Thus the study findings have direct implications for a large number of individuals globally.
"This study informs clinicians that AF is a marker of greater risk of cardiovascular events and mortality among diabetics, both men and women. Such patients should have their cardiovascular risk factors, such as blood pressure and cholesterol, controlled more aggressively."
The study also found that there was a significantly stronger association between AF and deaths from cardiovascular disease in women compared with men. Women with AF were twice as likely to die than women without AF, whereas men with AF were 50 per cent more likely to die then men without AF. As healthy women normally have a lower risk of death from heart disease than do men of a similar age, this increased risk in diabetic women with AF meant that the women's rates of death matched those of the men.
Prof Patel pointed out that AF was frequently undetected in diabetic patients. "The current analysis highlights the importance of actively evaluating diabetic patients for the presence of AF, to identify those at particularly high risk of cardiovascular events. Routine administration of blood pressure-lowering treatment, as well as greater use of antiplatelet or anticoagulant agents and statins, may be expected to reduce the incidence of a broad range of adverse outcomes in these patients."